{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000010","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.947165+00:00","generated_at":"2026-06-04T22:21:00.251018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial","bullets":["Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.","Cash $9.4M at Dec 31, 2023; subsequent $51M PIPE from institutional investors and JDRF T1D Fund closed Feb 28, 2024.","First Phase 3 trial of cadisegliatin for type 1 diabetes to enroll first patient in Q2 2024; top-line data expected by Q1 2026.","R&D expenses $13.6M in FY2023 (up 10% YoY); G&A expenses $11.9M (down 2% YoY).","Board reduced from 9 to 7; three new directors designated by new investors including Srinivas Akkaraju from Samsara."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000010","json":"https://secwatch.observer/filing/0001641489-24-000010.json","markdown":"https://secwatch.observer/filing/0001641489-24-000010.md","text":"https://secwatch.observer/filing/0001641489-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/0001641489-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/vtvt-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:21:00.251018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64a78ae512310f801dce4359ce4c77be775175fb","claim":"vTv Therapeutics Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000010/0001641489-24-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}